Clinical Trials Browser

OTHER × Adenocarcinoma of Lung × osimertinib × Clear all

NCT05528458 2026-04-28

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Phase 2 Recruiting

Adenocarcinoma of Lung

NCT04770688 2024-08-15

AUTOMAN

Phase 1/2 Completed

Adenocarcinoma of Lung, Neoplasm Metastasis